Genomic Health Inc. (GHDX)

33.08
0.17 0.52
NASDAQ : Health Technology
Prev Close 32.91
Open 32.70
Day Low/High 32.38 / 33.39
52 Wk Low/High 26.54 / 37.50
Volume 70.76K
Avg Volume 175.80K
Exchange NASDAQ
Shares Outstanding 34.78M
Market Cap 1.13B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Genomic Health (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Presents New Data Demonstrating Value Of Oncotype DX® To Optimize Breast Cancer Outcomes And Reduce Treatment Burden Throughout Disease Continuum

Genomic Health Presents New Data Demonstrating Value Of Oncotype DX® To Optimize Breast Cancer Outcomes And Reduce Treatment Burden Throughout Disease Continuum

New Data Supports Expanded Use of Oncotype DX Breast Recurrence Score® Test for Predicting Treatment Benefit in Neoadjuvant Setting

Genomic Health Announces Research Collaboration With Janssen Pharmaceuticals To Evaluate The Oncotype DX® Genomic Prostate Score™ Test For Potential Drug Development

Genomic Health Announces Research Collaboration With Janssen Pharmaceuticals To Evaluate The Oncotype DX® Genomic Prostate Score™ Test For Potential Drug Development

Additionally, Genomic Health Makes a $4M Equity Investment in Biocartis, Furthering Collaboration to Develop an IVD version of the Oncotype DX Breast Recurrence Score® Test

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests

Global Licensing Agreement Provides Genomic Health with Exclusive Rights to Cleveland Diagnostics' Proprietary IsoPSA™ Technology

Relative Strength Alert For Genomic Health

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health And Biocartis Announce Agreement To Develop An Idylla™ IVD Oncotype DX® Breast Cancer Test To Broaden Global Patient Access

Genomic Health And Biocartis Announce Agreement To Develop An Idylla™ IVD Oncotype DX® Breast Cancer Test To Broaden Global Patient Access

Strategic Collaboration Aimed at Exclusive Test Development and Commercialization of Proprietary Genomic Health Tests on the Idylla™ Platform

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.90, changing hands for $32.15/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Presents Data Demonstrating Importance Of Oncotype DX Breast Recurrence Score® Test In Predicting Outcomes Across Patient Populations At ESMO 2017

Genomic Health Presents Data Demonstrating Importance Of Oncotype DX Breast Recurrence Score® Test In Predicting Outcomes Across Patient Populations At ESMO 2017

New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive Disease and Experience Excellent Five-year Survival without Chemotherapy

Genomic Health Continues To Pioneer Genomic-based Cancer Diagnostics With Multiple Presentations At ESMO 2017 Congress

Genomic Health Continues To Pioneer Genomic-based Cancer Diagnostics With Multiple Presentations At ESMO 2017 Congress

New Data Reinforce Unmatched Value of the Oncotype DX Breast Recurrence Score® Test to Examine Tumor Biology Across Patient Populations

Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role Of Genomic Testing In Treatment Of Early Breast Cancer

Updated St. Gallen International Breast Cancer Guidelines Reinforce Important Role Of Genomic Testing In Treatment Of Early Breast Cancer

Oncotype DX® Test Endorsed for Guiding Treatment Decisions on Adjuvant Chemotherapy Both in Node-negative and in Node-positive Disease

Genomic Health Presents Data Further Demonstrating Ability Of Oncotype DX® Tests To Optimize Outcomes In Patients Across Cancer Types

Data from Eight Oncotype DX Studies Across Breast, Prostate and Kidney Cancers Presented at 2017 American Society of Clinical Oncology Annual Meeting

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $30.89, changing hands for $32.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Announces Presentation Of Eight Oncotype DX® Studies At The 2017 American Society Of Clinical Oncology Annual Meeting Reinforcing Unique Impact Across Cancer Types

Presentations in Breast and Prostate Cancers Highlight Ability of Tests to Answer Critical Clinical Questions and Optimize Treatment Outcomes

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.08/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALLY, CENX, DEL, DK, FWRD, GHDX, GWW, MLNX, QUAD, TSLX, WFM, WIRE Downgrades: AIMC, FTR, TRN Initiations: ACBI Read on to get TheStreet Quant Ratings' detailed report:

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.05, changing hands for $31.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Genomic Health Becomes Oversold (GHDX)

Genomic Health Becomes Oversold (GHDX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

GHDX Crosses Above Average Analyst Target

GHDX Crosses Above Average Analyst Target

In recent trading, shares of Genomic Health Inc have crossed above the average analyst 12-month target price of $31.94, changing hands for $32.26/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

5 Stocks to Trade for Big Breakout Gains

5 Stocks to Trade for Big Breakout Gains

These five stocks could be toxic for your portfolio in the month ahead.

TheStreet Quant Rating: C (Hold)